What happenedAccording to a filing with the Securities and Exchange Commission dated Aug. 12, 2025, Stevens Capital Management LP completely exited its position in Eli Lilly and Company (LLY -0.20%), by selling all 12,036 shares in Q2 2025. The estimated transaction value, based on the average price for the quarter ended June 30, 2025, was approximately $9.94 million. What else to knowThe following are the fund's top holdings post-filing at the end of the second quarter:Strategy (previously MicroStrategy): ...

Core Insights - Eli Lilly's aggressive push in the GLP-1 drug market has forced Novo Nordisk to lower its annual forecasts twice, with Tirzepatide becoming increasingly common on U.S. pharmacy shelves [1][3] - Eli Lilly's H1 2025 revenue reached $28.2862 billion, a 41% year-over-year increase, driven significantly by its diabetes business, which contributed nearly half of its revenue [1][3] Financial Performance - Eli Lilly's revenue breakdown for H1 2025: - U.S. market: $19.304 billion, up 43% - Europe: $4.963 billion, up 74% - Japan: $0.923 billion, up 11% - China: $0.917 billion, up 20% - Other markets: $2.18 billion, up 7% [1] - The diabetes segment, particularly Trulicity, Mounjaro, Humalog, and Jardiance, contributed $13.9728 billion [1] Product Performance - Tirzepatide's sales in H1 2025: - Mounjaro (diabetes version): $9.0407 billion, up 85% - Zepbound (weight loss version): $5.6933 billion, up 223% [2] - Zepbound's Q2 revenue was $3.381 billion, a 172% increase, while Novo Nordisk's Wegovy grew at 75% [3] Market Position - Eli Lilly's prescription share in the U.S. GLP-1RA market reached 57%, up from 53.3% in Q1, surpassing Novo Nordisk's 42.5% [2] - The revenue gap between Tirzepatide and Novo Nordisk's Semaglutide has narrowed to less than $2 billion [3] Competitive Landscape - Novo Nordisk's market challenges include a decline in growth expectations for Wegovy and Ozempic, leading to a significant drop in its market capitalization [3][4] - Analysts note that Eli Lilly's success is attributed to the superior efficacy of Tirzepatide and its established sales channels, which have been enhanced by its long-standing experience in the GLP-1 market [4]

It's not too late to invest in this company. Eli Lilly (LLY 0.73%) has been a terrific investment in recent years. Thanks to significant clinical progress and outstanding financial results, the company has become the largest healthcare player in the world: Eli Lilly's market cap was about $684 billion as of close of trading Aug. 1. That's some distance away from the $1 trillion mark. However, the drugmaker could become a $2 trillion stock within seven years. Here's why Eli Lilly could pull it off. Lilly cou ...

Core Viewpoint - Analysts expect Eli Lilly (LLY) to report quarterly earnings of $5.61 per share, reflecting a year-over-year increase of 43.1%, with revenues projected at $14.75 billion, up 30.5% from the previous year [1] Earnings Projections - The consensus EPS estimate has been revised downward by 1.5% in the past 30 days, indicating a reassessment by analysts [1][2] Key Metrics Forecast - Analysts predict 'Net Sales- Cyramza' at $246.20 million, a decrease of 1.1% year-over-year [4] - 'Net Sales- Humulin' is expected to be $206.10 million, down 7.8% year-over-year [4] - 'Net Sales- Humalog' is projected at $609.52 million, reflecting a decline of 3.5% from the previous year [4] - 'Net Sales- Forteo' is estimated at $62.76 million, down 10.2% year-over-year [5] - 'Net Sales- International-Forteo' is forecasted at $34.28 million, a decrease of 11% [5] - 'Net Sales- Cyramza (ROW)' is expected to reach $130.32 million, down 1.9% year-over-year [6] - 'Net Sales- Emgality (ROW)' is projected at $42.01 million, indicating a significant decline of 22.8% [6] - 'Net Sales- International-Alimta' is estimated at $17.05 million, down 20.3% from the previous year [6] - 'Net Sales- US-Humulin' is expected to be $154.98 million, down 8.5% year-over-year [7] - 'Net Sales- Emgality (US)' is projected at $135.67 million, reflecting a decrease of 1.4% [7] - 'Net Sales- US-Humalog' is estimated at $412.17 million, down 5.2% year-over-year [7] - 'Net Sales- US-Forteo' is expected to reach $28.73 million, indicating a decline of 8.8% [8] Stock Performance - Over the past month, shares of Lilly have returned -2.4%, contrasting with the Zacks S&P 500 composite's +0.6% change [8]

Core Insights - Eli Lilly reported a revenue of $12.73 billion for the quarter ended March 2025, marking a 45.2% increase year-over-year, with an EPS of $3.34 compared to $2.58 in the same quarter last year [1] - The revenue exceeded the Zacks Consensus Estimate of $12.62 billion by 0.86%, while the EPS fell short of the consensus estimate of $3.52 by 5.11% [1] Financial Performance - Key metrics indicate that Eli Lilly's shares have returned +9.9% over the past month, contrasting with a -0.7% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3] Sales Breakdown - Verzenio in the U.S. generated net sales of $657.60 million, below the average estimate of $720.57 million, reflecting a year-over-year increase of 3% [4] - Neuroscience products in the U.S. achieved net sales of $189.30 million, slightly above the average estimate of $188.66 million, with a year-over-year growth of 16% [4] - Geographic revenue from the U.S. reached $8.49 billion, slightly below the $8.50 billion estimate, representing a 49.1% year-over-year increase [4] - Humalog's net sales were $335.10 million, below the average estimate of $361.22 million, showing a year-over-year decline of 1% [4] - Cyramza's total net sales were $224.90 million, slightly below the estimate of $227.45 million, with a year-over-year decrease of 2.2% [4] - Humulin's net sales were $173.20 million, significantly below the estimate of $203.01 million, reflecting a 16% year-over-year decline [4] - Forteo's net sales were $66.60 million, exceeding the average estimate of $50.84 million, with an 8.7% year-over-year increase [4] - Erbitux's net sales were $149 million, slightly above the estimate of $146.04 million, indicating a 3% year-over-year increase [4] - Alimta's net sales were $28.20 million, significantly below the estimate of $46.13 million, showing a 59.4% year-over-year decline [4] - Other pharmaceuticals generated net sales of $212.90 million, slightly below the estimate of $213.18 million, reflecting a 12% year-over-year decline [4] - Oncology products achieved net sales of $1.95 billion, below the average estimate of $2.07 billion, with a year-over-year increase of 7.6% [4]